$177.82
1.04% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US09062X1037
Symbol
BIIB

Biogen Stock price

$177.82
-2.36 1.31% 1M
+44.63 33.51% 6M
+1.83 1.04% YTD
+27.82 18.55% 1Y
-99.10 35.79% 3Y
-65.13 26.81% 5Y
-93.55 34.47% 10Y
+136.11 326.35% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+1.83 1.04%
ISIN
US09062X1037
Symbol
BIIB
Industry

New AI Insights on Biogen Insights AI Insights on Biogen

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$26.1b
Enterprise Value
$28.4b
Net debt
$2.3b
Cash
$4.0b
Shares outstanding
146.7m
Valuation (TTM | estimate)
P/E
16.3 | 11.7
P/S
2.6 | 2.6
EV/Sales
2.8 | 2.8
EV/FCF
12.6
P/B
1.4
Financial Health
Equity Ratio
59.6%
Return on Equity
9.8%
ROCE
11.1%
ROIC
10.3%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$10.1b | $10.0b
EBITDA
$3.3b | $3.3b
EBIT
$2.9b | $2.9b
Net Income
$1.6b | $2.2b
Free Cash Flow
$2.3b
Growth (TTM | estimate)
Revenue
4.8% | 3.6%
EBITDA
16.5% | 7.5%
EBIT
15.2% | 7.5%
Net Income
-0.4% | 36.9%
Free Cash Flow
28.0%
Margin (TTM | estimate)
Gross
75.2%
EBITDA
33.1% | 32.6%
EBIT
28.5%
Net
16.0% | 22.3%
Free Cash Flow
22.5%
More
EPS
$10.9
FCF per Share
$15.4
Short interest
5.8%
Employees
8k
Rev per Employee
$1.3m
Show more

Create a Free Account to create an Biogen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Biogen Stock Analysis

Unlock Scores for Free

Analyst Opinions

42 Analysts have issued a Biogen forecast:

21x Buy
50%
21x Hold
50%

Analyst Opinions

42 Analysts have issued a Biogen forecast:

Buy
50%
Hold
50%

Financial data from Biogen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
10,066 10,066
5% 5%
100%
- Direct Costs 2,493 2,493
6% 6%
25%
7,574 7,574
4% 4%
75%
- Selling and Administrative Expenses 2,426 2,426
5% 5%
24%
- Research and Development Expense 1,780 1,780
14% 14%
18%
3,334 3,334
16% 16%
33%
- Depreciation and Amortization 466 466
25% 25%
5%
EBIT (Operating Income) EBIT 2,868 2,868
15% 15%
28%
Net Profit 1,609 1,609
0% 0%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Biogen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biogen Stock News

Positive
Seeking Alpha
4 days ago
Biogen Inc. shares, despite retail investor pessimism, rose 15.1% in 2025. Besides the successful launch of Leqembi, I highlight Skyclarys, an Nrf2 activator for the treatment of Friedreich's ataxia, as a driver of Biogen's EBIT growth. Its sales totaled $132.9 million in Q3, up 29.9% year-over-year.
Neutral
GlobeNewsWire
12 days ago
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results from the completed Phase 3 VALOR study and its open-label extension (OLE) study evaluating QALSODY® (tofersen) for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) with...
Neutral
Business Wire
25 days ago
TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, 14-day oral single course treatment for women with PPD. This first-of-its-kind treatment offers relief from depressive sympt...
More Biogen News

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Head office United States
CEO Christopher Viehbacher
Employees 7,605
Founded 1978
Website www.biogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today